{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:50:12Z","timestamp":1794408612261,"version":"4.9.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.leukres.2017.01.003","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T04:20:44Z","timestamp":1483676444000},"page":"55-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group"],"prefix":"10.1016","volume":"54","author":[{"given":"Noriyoshi","family":"Iriyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihide","family":"Tokuhira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoiku","family":"Takaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maho","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Nakazato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei-Ji","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Asou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2017.01.003_bib0005","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/10428199809058378","article-title":"Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal","volume":"29","author":"Aguiar","year":"1998","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2017.01.003_bib0010","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1200\/JCO.2010.33.4169","article-title":"Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"29","author":"Kantarjian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.003_bib0015","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.leukres.2010.10.027","article-title":"Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system","volume":"35","author":"Tauchi","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2017.01.003_bib0020","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.01.003_bib0025","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.01.003_bib0030","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.leukres.2005.10.015","article-title":"Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients","volume":"30","author":"Ramanarayanan","year":"2006","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2017.01.003_bib0035","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3904\/kjim.2014.29.2.250","article-title":"Chronic myeloid leukemia as a secondary malignancy after diffuse large B-cell lymphoma","volume":"29","author":"Lee","year":"2014","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.leukres.2017.01.003_bib0040","first-page":"2049","article-title":"A case of chronic myeloid leukemia following TS-1 therapy for advanced gastric cancer","volume":"33","author":"Higuchi","year":"2006","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.leukres.2017.01.003_bib0045","first-page":"970","article-title":"Therapy-related chronic myelogenous leukemia following RFM therapy in a patient with follicular lymphoma","volume":"55","author":"Shibazaki","year":"2014","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.leukres.2017.01.003_bib0050","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.003_bib0055","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.23923","article-title":"Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML Study Group","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2017.01.003_bib0060","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.01.003_bib0065","first-page":"481","article-title":"Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR","volume":"50","author":"Yagasaki","year":"2009","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.leukres.2017.01.003_bib0070","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12185-014-1649-0","article-title":"The European Treatment and Outcome Study score is associated with clinical outcomes and treatment response following European LeukemiaNet 2013 recommendations in chronic-phase chronic myeloid leukemia","volume":"100","author":"Iriyama","year":"2014","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2017.01.003_bib0075","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software EZR for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.leukres.2017.01.003_bib0080","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a National Population-Based Cohort Study","volume":"33","author":"Granfeldt Ostgard","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.003_bib0085","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL","volume":"112","author":"Azam","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2017.01.003_bib0090","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.leukres.2013.10.022","article-title":"Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: study by the Nagasaki CML Study Group","volume":"38","author":"Itonaga","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2017.01.003_bib0095","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.003_bib0100","doi-asserted-by":"publisher","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2017.01.003_bib0105","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","article-title":"CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia","volume":"117","author":"Makishima","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.01.003_bib0110","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.01.003_bib0115","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2017.01.003_bib0120","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1269\/jrr.32.SUPPLEMENT2_257","article-title":"Cytogenetic and molecular changes in leukemia among atomic bomb survivors","volume":"32","author":"Kamada","year":"1991","journal-title":"J. Radiat. Res."},{"key":"10.1016\/j.leukres.2017.01.003_bib0125","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1269\/jrr.32.SUPPLEMENT2_14","article-title":"Atomic bomb and leukemia","volume":"32","author":"Ichimaru","year":"1991","journal-title":"J. Radiat. Res."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617300036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617300036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T08:27:40Z","timestamp":1536136060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617300036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":25,"alternative-id":["S0145212617300036"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.01.003","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}